Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
Digestive Diseases (Basel, Switzerland)|March 7, 2024
Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA RegistryIván Guerra, Francisco Barros, María Chaparro, et al.
Therapeutic Advances in Gastroenterology|February 24, 2026
Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCUFrancisco Mesonero, Yamile Zabana, Agnès Fernández-Clotet, et al.
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.
Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 15, 2025
Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO RegistryLaura Palomino, Marta Velasco Rodríguez-Belvís, María José Casanova, et al.
The American Journal of Gastroenterology|January 30, 2023
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and SafetyMaría Chaparro, Diana Acosta, Cristina Rodríguez, et al.
Inflammatory Bowel Diseases|February 15, 2022
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN StudyMaría Chaparro, Iria Baston-Rey, Estela Fernández-Salgado, et al.
Journal of Clinical Medicine|August 12, 2022
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on UstekinumabMaría Chaparro, Iria Baston-Rey, Estela Fernández Salgado, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
United European Gastroenterology Journal|December 6, 2025
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA RegistryMíriam Mañosa, Margalida Calafat, Elena Ricart, et al.
Pageof 19